SU111901A1 - The method of treatment of toxicosis of early pregnancy with the drug splenin - Google Patents
The method of treatment of toxicosis of early pregnancy with the drug spleninInfo
- Publication number
- SU111901A1 SU111901A1 SU586183A SU586183A SU111901A1 SU 111901 A1 SU111901 A1 SU 111901A1 SU 586183 A SU586183 A SU 586183A SU 586183 A SU586183 A SU 586183A SU 111901 A1 SU111901 A1 SU 111901A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- toxicosis
- drug
- splenin
- treatment
- pregnancy
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Препарат спленин примен етс пе только как лечебное средство дл лечени токсикозов беременности , но и как профилактическое средство, так как он помогает предотвратить переход легких начальных форм токсикоза в более т желую форму.The drug Splenin is used not only as a therapeutic agent for the treatment of pregnancy toxicosis, but also as a prophylactic agent, since it helps to prevent the lung from the initial forms of toxicosis from becoming more severe.
Согласно изобретению, препарат рекомендуетс примен ть в виде подкожных и преимущественно в виде внутримышечных инъекций. При лечении токсикозов беременности его назначают следующим образом:According to the invention, the preparation is recommended to be used in the form of subcutaneous and mainly in the form of intramuscular injections. In the treatment of pregnancy toxicosis, it is prescribed as follows:
а)При токсикозе беременности первой степени - по 1 мл ежедневно в течение 8-10 дней.a) In case of toxicosis of pregnancy of the first degree - 1 ml daily for 8-10 days.
б)При токсикозе беременности второй степени-по 2 мл ежедневно одномоментно или по 1 мл 2 раза в день в течение 10-12 дней. В упорных случа х дозировку препарата рекомендуетс удвоить, т. е. по 2 мл .спленина 2 раза в день-утром и вечером.b) In case of toxicosis of second degree pregnancy, 2 ml daily at a time or 1 ml 2 times a day for 10-12 days. In resistant cases, the dosage of the drug is recommended to double, i.e., 2 ml of splenin 2 times a day, in the morning and evening.
В случае рецидива курс лечени повтор ют.In case of relapse, the treatment is repeated.
в)При токсикозах третьей степени спленин примен ют в комплексе с методами, восстанавливающими потерю жидкости организмом, по 4 . ежедневно (по 2 мл два раза в день-утром и вечером) в течение 10-15 дней.c) In case of toxicosis of the third degree, splenin is used in combination with methods that restore body fluid loss, according to 4. daily (2 ml twice a day, in the morning and in the evening) for 10-15 days.
г)Препарат в указанной дозировке рекомендуетс также примен ть как один из важных компонентов комплексного лечени токсикозов беременности: внутримыщечные инъекции спленина, внутривенные вЛ1Г15ани физиологического раствора , вливание 40%-ного раствора глюкозы, брома и др.d) The drug in the indicated dosage is also recommended to be used as one of the important components of the complex treatment of toxicosis of pregnancy: intramuscular splenin injections, intravenous lymphocytes, saline, 40% glucose solution, bromine, etc.
Препарат спленин не вызывает никаких побочных влени даже при д.тительном его применении.The drug Splenin does not cause any side effects, even if it is used closely.
Фармакологический комитет Ученого совета Министерства здравоохранени СССР разрещил щирокое применение препарата в медиципской практике.The pharmacological committee of the Scientific Council of the USSR Ministry of Health has allowed widespread use of the drug in medical practice.
Пред м е т и з о б р е т е н и Prevention and Consideration
Способ лечени токсикозов ранних сроков беременности препаратом спленин, отличающийс тем, что препарат примен ют в виде подкожных и преимущественпо внутримышечпых инъекций один или в комплексе с другими видами терапии , например, с введением 40%ного раствора глюкозы, физиологического раствора и др., при токсикозах беременности первой степениThe method of treatment of toxicosis of early pregnancy with the drug splenin, characterized in that the drug is used in the form of subcutaneous and predominantly by intramuscular injections alone or in combination with other therapies, for example, with the introduction of 40% glucose solution, saline, etc., with toxicosis first degree pregnancy
по I мл ежедневно в течение 8- 10 дней, при токсикозах беременности второй степени по 2 л ежедневно в течение 10-12 дней, а при упорных случа х по 4 м.л в день, и при токсикозах беременности третьей степени по 4 мл в течение 10-15 дней.1 ml daily for 8–10 days, for second-degree pregnancy toxicosis, 2 liters daily for 10–12 days, and 4 ml a day for persistent cases, and 4 ml for third-degree pregnancy toxicosis, within 10-15 days.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU586183A SU111901A1 (en) | 1957-11-15 | 1957-11-15 | The method of treatment of toxicosis of early pregnancy with the drug splenin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU586183A SU111901A1 (en) | 1957-11-15 | 1957-11-15 | The method of treatment of toxicosis of early pregnancy with the drug splenin |
Publications (1)
Publication Number | Publication Date |
---|---|
SU111901A1 true SU111901A1 (en) | 1957-11-30 |
Family
ID=48384508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU586183A SU111901A1 (en) | 1957-11-15 | 1957-11-15 | The method of treatment of toxicosis of early pregnancy with the drug splenin |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU111901A1 (en) |
-
1957
- 1957-11-15 SU SU586183A patent/SU111901A1/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soloff et al. | Syndrome of salt depletion: induced by a regimen of sodium restriction and sodium diuresis | |
Malpas et al. | Rubidomycin in acute leukaemia in adults | |
Geller et al. | Effects of cortisone and antibiotics on lethal action of endotoxins in mice. | |
SU111901A1 (en) | The method of treatment of toxicosis of early pregnancy with the drug splenin | |
Hirsh et al. | EVALUATION OF SUBCUTANEOUS CALCIUM HEPARIN THERAPY IN THE TREATMENT OF THROMBO‐EMBOLIC DISEASE | |
Schwartz et al. | Treatment of painful crises of sickle cell disease: A double blind study | |
JOHANSEN et al. | Digital ischemia complicating pneumococcal sepsis: reversal with sympathetic blockade | |
Davis et al. | The effect of intravenous colchicine on acute gout | |
Fisher et al. | The subcutaneous administration of the sodium salt of para-aminosalicylic acid in the treatment of tuberculosis | |
Winer et al. | The Value of Sulfathiazole Ointment in the Treatment of Pyogenic Infections of the Skin | |
SU301951A1 (en) | MEDICINE | |
Vick et al. | Supplementary role of hydralazine in reversal of endotoxin shock with metaraminol and hydrocortisone | |
Boyd | Hyaluronidase as an aid to administration of fluid in the treatment of dehydration in infants | |
Parker | Further Observations on the Use of Combined Calcium Anti-Histamine Therapy in Dermatology | |
Hinshaw et al. | Technique of streptomycin administration | |
Wrong | Penicillin therapy in skin infections | |
Cohen et al. | Continuous intravenous administration of ACTH | |
SU459228A1 (en) | Medicine | |
Shrank et al. | Chilblain Lupus Erythiematosus | |
Yamamoto | Studies on Treatment of Wakana Disease I. Anchylostomocidal effects of various drugs against hookworm larvae | |
SU1264944A1 (en) | Method of treatment of patients ill with acute myocardial infarction and unstable stenocardia | |
Walsh et al. | Accidental intra-arterial injection of oxophenarsine hydrochloride (Mapharsen) | |
SU552085A1 (en) | Medication for the treatment of blood coagulation disorders in thrombocytopenic conditions of various origins and for the stimulation of erythrophosphatid hemopoiesis | |
SU109348A1 (en) | Method for expansion of coronary and peripheral vessels | |
SU391832A1 (en) | PREPARATION |